Max Mamonkin, Associate Professor at Columbia shared March Biosciences’s post on LinkedIn, adding:
“This project was inspired by the beautiful, innovative, and groundbreaking work of Andras Heczey and his team in HCC and hepatoblastoma.
We combined his innovation with new ideas developed in my lab at Baylor by Chiou-Tsun (Ray) Tsai and Hiro Watanabe. And thank you Helen Heslop for supporting the grant.
Very excited for this new direction at March Bio.”
Quoting March Biosciences’s post:
“March Biosciences is pleased to announce that we have received a Fast-Track SBIR award of up to $2.58M from The National Institutes of Health to advance a novel CAR T-cell therapy for hepatocellular carcinoma, the most common form of liver cancer.
This program leverages our synapse-stabilizing receptor (SSR) platform, a modular approach to enhancing CAR T-cell targeting of solid tumors.
We’re grateful to the NIH and NCI for supporting this work, to our collaborators at Baylor College of Medicine, including Dr. Chiou-Tsun (Ray) Tsai, and to the March team led by Dr. Eric Smith.
This project is 100% federally funded by the NCI under Award Number R44CA314963.”
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio